300 related articles for article (PubMed ID: 9028722)
1. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM.
Kong MF; King P; Macdonald IA; Stubbs TA; Perkins AC; Blackshaw PE; Moyses C; Tattersall RB
Diabetologia; 1997 Jan; 40(1):82-8. PubMed ID: 9028722
[TBL] [Abstract][Full Text] [Related]
2. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM.
Kong MF; Stubbs TA; King P; Macdonald IA; Lambourne JE; Blackshaw PE; Perkins AC; Tattersall RB
Diabetologia; 1998 May; 41(5):577-83. PubMed ID: 9628276
[TBL] [Abstract][Full Text] [Related]
3. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.
Kolterman OG; Schwartz S; Corder C; Levy B; Klaff L; Peterson J; Gottlieb A
Diabetologia; 1996 Apr; 39(4):492-9. PubMed ID: 8778001
[TBL] [Abstract][Full Text] [Related]
4. Effect of euglycaemic hyperinsulinaemia on gastric emptying and gastrointestinal hormone responses in normal subjects.
Kong MF; King P; Macdonald IA; Blackshaw PE; Perkins AC; Armstrong E; Buchanan KD; Tattersall RB
Diabetologia; 1998 Apr; 41(4):474-81. PubMed ID: 9562353
[TBL] [Abstract][Full Text] [Related]
5. The role of prandial pramlintide in the treatment of adolescents with type 1 diabetes.
Rodriguez LM; Mason KJ; Haymond MW; Heptulla RA
Pediatr Res; 2007 Dec; 62(6):746-9. PubMed ID: 17957149
[TBL] [Abstract][Full Text] [Related]
6. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.
Singh-Franco D; Robles G; Gazze D
Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279
[TBL] [Abstract][Full Text] [Related]
7. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
Ryan GJ; Jobe LJ; Martin R
Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288
[TBL] [Abstract][Full Text] [Related]
8. Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue.
Kolterman OG; Gottlieb A; Moyses C; Colburn W
Diabetes Care; 1995 Aug; 18(8):1179-82. PubMed ID: 7587855
[TBL] [Abstract][Full Text] [Related]
9. Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus.
Vella A; Lee JS; Camilleri M; Szarka LA; Burton DD; Zinsmeister AR; Rizza RA; Klein PD
Neurogastroenterol Motil; 2002 Apr; 14(2):123-31. PubMed ID: 11975712
[TBL] [Abstract][Full Text] [Related]
10. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
[TBL] [Abstract][Full Text] [Related]
11. Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects.
Orskov L; Nyholm B; Yde Hove K; Gravholt CH; Møller N; Schmitz O
Diabet Med; 1999 Oct; 16(10):867-74. PubMed ID: 10547215
[TBL] [Abstract][Full Text] [Related]
12. Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study.
Chase HP; Lutz K; Pencek R; Zhang B; Porter L
J Pediatr; 2009 Sep; 155(3):369-73. PubMed ID: 19464026
[TBL] [Abstract][Full Text] [Related]
13. Euglycaemic hyperinsulinaemia does not affect gastric emptying in type I and type II diabetes mellitus.
Kong MF; King P; Macdonald IA; Blackshaw PE; Horowitz M; Perkins AC; Armstrong E; Buchanan KD; Tattersall RB
Diabetologia; 1999 Mar; 42(3):365-72. PubMed ID: 10096791
[TBL] [Abstract][Full Text] [Related]
14. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.
Fineman M; Weyer C; Maggs DG; Strobel S; Kolterman OG
Horm Metab Res; 2002 Sep; 34(9):504-8. PubMed ID: 12384827
[TBL] [Abstract][Full Text] [Related]
15. Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes.
Thompson RG; Gottlieb A; Organ K; Koda J; Kisicki J; Kolterman OG
Diabet Med; 1997 Jul; 14(7):547-55. PubMed ID: 9223392
[TBL] [Abstract][Full Text] [Related]
16. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.
Fineman MS; Koda JE; Shen LZ; Strobel SA; Maggs DG; Weyer C; Kolterman OG
Metabolism; 2002 May; 51(5):636-41. PubMed ID: 11979398
[TBL] [Abstract][Full Text] [Related]
17. Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans?
Asmar M; Bache M; Knop FK; Madsbad S; Holst JJ
J Clin Endocrinol Metab; 2010 May; 95(5):2367-75. PubMed ID: 20194711
[TBL] [Abstract][Full Text] [Related]
18. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
[TBL] [Abstract][Full Text] [Related]
19. Importance of changes in gastric emptying for postprandial plasma glucose fluxes in healthy humans.
Woerle HJ; Albrecht M; Linke R; Zschau S; Neumann C; Nicolaus M; Gerich J; Göke B; Schirra J
Am J Physiol Endocrinol Metab; 2008 Jan; 294(1):E103-9. PubMed ID: 17971511
[TBL] [Abstract][Full Text] [Related]
20. Glucose control is not improved by accelerating gastric emptying in patients with type 1 diabetes mellitus and gastroparesis. a pilot study with cisapride as a model drug.
Lehmann R; Honegger RA; Feinle C; Fried M; Spinas GA; Schwizer W
Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):255-61. PubMed ID: 12951630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
